The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region.

While our STAM™ model develops mild liver fibrosis, the CCl4 model develops severe cirrhosis-like fibrosis.

We also offer pharmacological studies with the positive control ”Valsartan”.

As its study period is relatively short, only 4 weeks, the model is useful for in-vivo screening study against liver fibrosis.

Besides the CCl₄ model, we also have a variety of other models related to liver diseases such as the STAM^TM model, the Bile duct ligation (BDL)-induced cholestatic liver disease and acute liver failure models.